secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-01-12T23:59:59+00:00
Accession:  0000950170-24-004262
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics CFO Jason Amello resigns; Charles Schoch named interim CFO
------------------------------------------------------------------------------

- Jason A. Amello resigned as CFO effective Jan 12, 2024, to pursue another opportunity.
- Board appointed Charles Schoch as interim CFO, effective Jan 12, 2024.
- Schoch had served as VP of Finance and Corporate Controller since March 2023.
- Schoch's annual base salary increased to $325,000 as interim CFO.
- Schoch is a CPA with prior experience at Corbus Pharmaceuticals and PwC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/0000950170-24-004262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024004262/cadl-20240112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-004262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer